Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-13 in Moderate to Severe Ulcerative Colitis
NCT05785715Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Apr 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of amelenodor in ulcerative colitis (UC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Modified Mayo Score at 12 weeks. Started Apr 2023; status: terminated.
02
Drugs
amelenodor
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05785715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785715.